Michael Wang
MD
Professor
👥Biography 个人简介
Michael Wang at MD Anderson has been a leading researcher in mantle cell lymphoma (MCL), contributing to the development of ibrutinib, venetoclax, and subsequently brexucabtagene autoleucel (ZUMA-2 trial) for relapsed/refractory MCL. His work on non-covalent (reversible) BTK inhibitors (pirtobrutinib) for BTK inhibitor-resistant MCL addresses the critical challenge of resistance after covalent BTK inhibitor therapy in this typically incurable lymphoma.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Michael Wang 的研究动态
Follow Michael Wang's research updates
留下邮箱，当我们发布与 Michael Wang（MD Anderson Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment